RecruitingNot Applicable

Influence of Body Composition on Chemotherapy Outcomes in Localized Breast Cancer

France48 participantsStarted 2023-10-25

Plain-language summary

The purpose of this study is to determine if pharmacokinetics of docetaxel is modified by the body composition (assessed by the BMI but also by CT-scan) in patients treated by docetaxel as adjuvant treatment of a localized breast cancer

Who can participate

Age range

18 Years

Sex

FEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Woman older than * Early breast cancer * CT-scan of less than 3 months, including L3 level * Indication of docetaxel at 100 mg/m² as adjuvant CT Exclusion Criteria: * HER2 amplified or triple negative tumors * Pregnant or breastfeeding women * Patients under guardianship or curatorship * Concomitant administration of another cytotoxic drug or targeted therapy * Psychosocial disorder * Administration of another cytotoxic drug or targeted therapy within 20 days prior to blood collection

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Comparison of docetaxel area under courb between obese and lean patients

Timeframe: 8 hours after the end of first cycle of docetaxel

Trial details

NCT IDNCT05858398

SponsorCentre Henri Becquerel

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-05-02

Contact for this trial

Florian Clatot, Prof

+33232082231 florian.clatot@chb.unicancer.fr

View on ClinicalTrials.gov More Breast Cancer trials